Corey T. McMillan

The overall mission of my integrative neuroscience lab is to use multimodal and bioinformatic approaches to improve our understanding of the biological basis of neurodegenerative conditions. My lab aims to develop robust biomarkers that can be used to better diagnose neurodegenerative diseases, accelerate drug discovery of disease-modifying agents, and to define essential clinical trial endpoint measures. My clinical-translation research program focuses on two classes of neurodegenerative proteinopathies including the misfolded tau protein that contributes to Alzheimer’s disease (AD), primary age-related tauopathy (PART), and frontotemporal lobar degeneration (FTLD), as well as the TDP-43 protein that contributes to a spectrum of FTLD and amyotrophic lateral sclerosis (ALS). My lab emphasizes biologically-grounded hypotheses with novel analytic and multimodal approaches integrating MRI and PET imaging modalities with genomics and clinical datasets.